These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 476594)
1. Adjuvant chemotherapy of breast cancer. Cooper RG; Holland JF; Glidewell O Cancer; 1979 Sep; 44(3):793-8. PubMed ID: 476594 [TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501 [TBL] [Abstract][Full Text] [Related]
4. Adverse effect of radiotherapy on adjuvant chemotherapy for carcinoma of the breast. Holland JF; Glidewell O; Cooper RG Surg Gynecol Obstet; 1980 Jun; 150(6):817-21. PubMed ID: 7376042 [TBL] [Abstract][Full Text] [Related]
5. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L; J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260 [TBL] [Abstract][Full Text] [Related]
6. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258 [TBL] [Abstract][Full Text] [Related]
7. Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival. Manni A; Trujillo JE; Pearson OH Cancer Treat Rep; 1980 Jan; 64(1):111-6. PubMed ID: 6155207 [TBL] [Abstract][Full Text] [Related]
9. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study. Rivkin SE; Green S; Metch B; Jewell WR; Costanzi JJ; Altman SJ; Minton JP; O'Bryan RM; Osborne CK J Clin Oncol; 1993 Sep; 11(9):1710-6. PubMed ID: 8355037 [TBL] [Abstract][Full Text] [Related]
10. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial. Muss HB; White DR; Richards F; Cooper MR; Stuart JJ; Jackson DV; Rhyne L; Spurr CL Cancer; 1978 Nov; 42(5):2141-8. PubMed ID: 363253 [TBL] [Abstract][Full Text] [Related]
11. Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity. Hirshaut Y; Kesselheim H Cancer; 1983 Jun; 51(11):1998-2004. PubMed ID: 6687698 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study. Rivkin SE; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi JJ; Hoogstraten B; Athens J; Maloney T; Osborne CK J Clin Oncol; 1989 Sep; 7(9):1229-38. PubMed ID: 2671283 [TBL] [Abstract][Full Text] [Related]
13. [Adjuvant endocrine therapy and chemotherapy of breast cancer (author's transl)]. Heuson JC; Paridaens R Rev Med Brux; 1982 Apr; 3(4):209-16. PubMed ID: 7046007 [No Abstract] [Full Text] [Related]
14. Combination chemotherapy in disseminated carcinoma of the breast. Kaufman S; Goldstein M Surg Gynecol Obstet; 1973 Jul; 137(1):83-6. PubMed ID: 4714324 [No Abstract] [Full Text] [Related]
15. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477 [TBL] [Abstract][Full Text] [Related]
16. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326 [TBL] [Abstract][Full Text] [Related]
17. An evaluation of five drug combination chemotherapy in the management of recurrent carcinoma of the breast. Lee JM; Abeloff MD; Lenhard RE; Baker RR Surg Gynecol Obstet; 1974 Jan; 138(1):77-80. PubMed ID: 4809006 [No Abstract] [Full Text] [Related]
18. Chemotherapy of metastatic breast cancer in postmenopausal women: a controlled trial of cyclophosphamide versus a five-drug combination of cyclophosphamide, vincristine, methotrexate, 5-fluorouracil and prednisone. Mouridsen HT; Palshof T Prog Clin Biol Res; 1977; 12():459-66. PubMed ID: 335404 [No Abstract] [Full Text] [Related]
19. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820 [TBL] [Abstract][Full Text] [Related]
20. Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Smalley RV; Murphy S; Huguley CM; Bartolucci AA Cancer Res; 1976 Nov; 36(11 Pt 1):3911-6. PubMed ID: 975039 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]